Download PDF
Arzneimittelforschung 2012; 62(01): 9-13
DOI: 10.1055/s-0031-1291361
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Bioequivalence Evaluation of Cefdinir in Healthy Fasting Subjects

J. Chen
1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
,
B. Jiang
1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
,
H. Lou
1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
,
L. Yu
1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
,
Z. Ruan
1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
› Author Affiliations
Further Information

Publication History

received 15 September 2011

accepted 17 October 2011

Publication Date:
10 January 2012 (online)

    Permissions and Reprints

Abstract

A simple and sensitive HPLC method was developed to determine cefdinir (CAS 91832-40-5) in human plasma. The method was validated by investigating the accuracy and precision for intra- and inter-day runs in a linear concentration from 0.05–2.0 µg/ml. The object of this study was to compare the bioavailability of cefdinir capsule (reference) and cefdinir granule (test) containing 100 mg of cefdinir. A randomized, open-label, single-dose, 2-way crossover bioequivalence study in 20 healthy, Chinese, male subjects was conducted. A 1-week wash-out period was applied. Blood samples were collected before and with 10 h after drug administration. The formulations were compared using the following pharmacokinetic parameters: AUC0-t, AUC0-∞ and C max. The 90% confidence interval (CI) of the ratios of log-transformed AUC0-t and AUC0-∞ were used to assess bioequivalence between the 2 formulations using the equivalence interval of 80 and 125%. The results showed that the 90% CI of the ratios of AUC0-t, AUC0-∞ and C max were 102.5% (94.7–111.0%), 103.4% (94.8–112.7%) and 106.4% (97.0–116.7%), respectively, which indicated 2 formulations of cefidinir are bioequivalent. Both treatments showed similar tolerability and safety.

Key words

Cefdinir - HPLC - CAS 91832-40-5 - protein precipitation - pharmacokinetics - bioequivalence
 

  • References

  • 1 Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs 2004; 64: 1433-1464
    CrossrefPubMedGoogle Scholar
  • 2 Okamoto Y, Itoh K, Namiki Y et al. Method development for the determination of cefdinir and its related substances by high-performance liquid chromatography. J Pharm Biomed Anal 1996; 14: 739-748
    CrossrefPubMedGoogle Scholar
  • 3 Cook PJ, Andrews JM, Wise R et al. Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments. J Antimicrob Chemother 1996; 37: 331-339
    CrossrefPubMedGoogle Scholar
  • 4 Lepsy CS, Guttendorf RJ, Kugler AR et al. Effects of organic anion, organic cation, and dipeptide transport inhibitors on cefdinir in the isolated perfused rat kidney. Antimicrob Agents Chemother 2003; 47: 689-696
    CrossrefPubMedGoogle Scholar
  • 5 Hishida A, Ohishi K, Nagashima S et al. Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. Antimicrob Agents Chemother 1998; 42: 1718-1721
    PubMedGoogle Scholar
  • 6 Chen ZJ, Zhang J, Yu JC et al. Selective method for the determination of cefdinir in human plasma using liquid chromatography electrospray ionization tandam mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 834: 163-169
    PubMedGoogle Scholar
  • 7 Fujita T, Nakamura K, Yamazaki A et al. Effect of L-phenylalanine supplementation and a high-protein diet on pharmacokinetics of cefdinir in healthy volunteers: an exploratory study. J Clin Pharm Ther 2007; 32: 277-285
    CrossrefPubMedGoogle Scholar